(Q46022495)

18 December 2017

title

Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population. (English)

1 reference

18 December 2017

author

Michael B. Nichol

5

1 reference

18 December 2017

Steven J Jacobsen

7

1 reference

18 December 2017

Lauren P Wallner

1

object named as

Lauren P Wallner

1 reference

18 December 2017

author name string

Stanley K Frencher

2

1 reference

18 December 2017

Jin-Wen Y Hsu

3

1 reference

18 December 2017

Chun R Chao

4

1 reference

18 December 2017

Ronald K Loo

6

1 reference

18 December 2017

publication date

15 January 2013

1 reference

18 December 2017

published in

BJU International

1 reference

18 December 2017

volume

111

1 reference

18 December 2017

issue

8

1 reference

18 December 2017

page(s)

1245-1252

1 reference

18 December 2017

Mortality results from a randomized prostate-cancer screening trial

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Effect of Inflammation and Benign Prostatic Hyperplasia on Elevated Serum Prostate Specific Antigen Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened P

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Prostate specific antigen best practice statement: 2009 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Impact of race and baseline PSA on longitudinal PSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Comparability of the tandem-R andIMx assays for the measurement of serum prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11651.X

10.1111/J.1464-410X.2012.11651.X

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017